(Q38676257)

English

The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.

scientific article published on 17 July 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

fatty liver disease

0 references

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

Zobair M Younossi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Elizabeth M. Brunt

8

object named as

Elizabeth M Brunt

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

3

object named as

Joel E Lavine

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Naga Chalasani

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Michael Charlton

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Kenneth Cusi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Mary Rinella

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Stephen A Harrison

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Arun J Sanyal

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

language of work or name

0 references

publication date

29 September 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

67

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

328-357

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Management of NAFLD: a stage-based approach

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Pharmacotherapy for Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Non-alcoholic fatty liver disease and liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Fatty liver incidence and predictive variables

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

NAFLD: a multisystem disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Epidemiology and natural history of non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Current and emerging medications for overweight or obesity in people with comorbidities

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Fatty infiltration of liver in hyperlipidemic patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Chronic liver disease among Alaska-Native people, 2003-2004.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Chronic liver disease among two American Indian patient populations in the southwestern United States, 2000-2003.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The Prevalence of Metabolic Syndrome In Non-alcoholic Fatty Liver Disease; A Population-Based Study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Factors associated or related to with pathological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Non-alcoholic fatty liver disease--a common and benign finding in octogenarian patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Non-alcoholic fatty liver disease in older people.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The natural history of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Incidence and natural course of fatty liver in the general population: the Dionysos study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Liver transplantation and non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long term prognosis of fatty liver: risk of chronic liver disease and death.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long-term follow-up of patients with nonalcoholic fatty liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Endpoints and clinical trial design for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

What should we recommend to our patients with NAFLD regarding alcohol use?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Gaps in recognition and evaluation of incidentally identified hepatic steatosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Heritability of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Liver fat content, evaluated through semi-quantitative ultrasound measurement, is associated with impaired glucose profiles: a community-based study in Chinese

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Intrapulpal temperature changes during root surface irradiation with dual-wavelength laser (2780 and 940 nm): in vitro study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A histologic scoring system for prognosis of patients with alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Histopathology of pediatric nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Association between puberty and features of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Pathological features of fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Metformin in non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Pioglitazone use and risk of bladder cancer: population based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Vitamin E and all-cause mortality: a meta-analysis

2 references

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Bariatric surgery and long-term cardiovascular events.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long-term mortality after gastric bypass surgery

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A Systematic Review of Bariatric Surgery in Patients with Liver Cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Alcohol consumption appears to protect against non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long-term follow-up of patients with NAFLD and elevated liver enzymes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Fatty liver is an independent predictor of early carotid atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Identifying sarcopenia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Estimating glomerular filtration rate from serum creatinine and cystatin C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil".

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Weight change and obesity after liver transplantation: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Mechanisms involved in the side effects of glucocorticoids

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

AASLD guidelines for the treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Prevalence of fatty liver in children and adolescents.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Advances in pediatric nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic Fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

21 January 2018

Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Independent effects of physical activity in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Bilateral traumatic chylothorax treated by thoracic duct embolization: a rare treatment for an uncommon problem

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased perioperative mortality following bariatric surgery among patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.29367

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.29367

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28714183%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38676257&oldid=1564526568"